Antihypertensive and cardioprotective effects of the dipeptide isoleucine-tryptophan and whey protein hydrolysate
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
AimsAngiotensin-converting enzyme inhibitors are treatment of choice in hypertensive patients. Clinically used inhibitors exhibit a structural similarity to naturally occurring peptides. This study evaluated antihypertensive and cardioprotective effects of ACE-inhibiting peptides derived from food proteins in spontaneously hypertensive rats.
Methods and ResultsIsoleucine-tryptophan (invitro IC50 for ACE= 0.7 m), a whey protein hydrolysate containing an augmented fraction of isoleucine-tryptophan, or captopril was given to spontaneously hypertensive rats (n=60) over 14weeks. Two further groups, receiving either no supplement (Placebo) or intact whey protein, served as controls. Systolic blood pressure age-dependently increased in the Placebo group, whereas the blood pressure rise was effectively blunted by isoleucine-tryptophan, whey protein hydrolysate and captopril (-423, -38 +/- 5, -55 +/- 4mm Hg vs. Placebo). At study end, myocardial mass was lower in isoleucine-tryptophan and captopril groups but only partially in the hydrolysate group. Coronary flow reserve (1m adenosine) was improved in isoleucine-tryptophan and captopril groups. Plasma ACE activity was significantly decreased in isoleucine-tryptophan, hydrolysate and captopril groups, but in aortic tissue only after isoleucine-tryptophan or captopril treatment. This was associated with lowered expression and activity of matrix metalloproteinase-2. Following isoleucine-tryptophan and captopril treatments, gene expression of renin was significantly increased indicating an active feedback within renin-angiotensin system.
ConclusionWhey protein hydrolysate and isoleucine-tryptophan powerfully inhibit plasma ACE resulting in antihypertensive effects. Moreover, isoleucine-tryptophan blunts tissue ACE activity, reduces matrix metalloproteinase-2 activity and improves coronary flow reserve. Thus, whey protein hydrolysate and particularly isoleucine-tryptophan may serve as innovative food additives with the goal of attenuating hypertension.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 167-176 |
Seitenumfang | 10 |
Fachzeitschrift | Acta Physiologica Scandinavica |
Jahrgang | 215 |
Ausgabenummer | 4 |
Publikationsstatus | Veröffentlicht - Dez. 2015 |
Peer-Review-Status | Ja |
Externe IDs
Scopus | 84982095574 |
---|---|
WOS | 000363880900005 |
researchoutputwizard | legacy.publication#66758 |
researchoutputwizard | legacy.publication#67439 |
ORCID | /0000-0002-8047-2774/work/142241812 |
Schlagworte
Schlagwörter
- angiotensin-converting enzyme, arterial hypertension, cardiac hypertrophy, matrix metalloproteinases, whey proteins, I-CONVERTING-ENZYME, BLOOD-PRESSURE, SOUR MILK, HYPERTENSIVE SUBJECTS, HEART-FAILURE, ANGIOTENSIN, INHIBITORS, RAT, PEPTIDES, TISSUE